Halozyme Therapeutics (HALO) Common Equity (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Common Equity data on file, last reported at $219.6 million in Q1 2026.

• On a quarterly basis, Common Equity fell 54.46% year-over-year to $219.6 million in Q1 2026; TTM through Mar 2026 was $219.6 million, a 54.46% decrease from a year earlier, with the FY2025 full-year figure at $48.8 million, down 86.58% from the prior year.
• Common Equity for Q1 2026 stood at $219.6 million, up from $48.8 million in the prior quarter.
• Over the last five years, Common Equity for HALO reached as high as $503.9 million in Q3 2025 and fell as low as $48.8 million in Q4 2025.
• Historically, Common Equity has averaged $249.5 million across 5 years, with a median of $249.2 million in 2023.
• Across the five-year window, Common Equity surged 334.11% in 2024 and sank 86.58% in 2025, its largest moves.
• Year by year, Common Equity stood at $169.8 million in 2022, then tumbled by 50.64% to $83.8 million in 2023, then jumped by 334.11% to $363.8 million in 2024, then sank by 86.58% to $48.8 million in 2025, then surged by 349.94% to $219.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $219.6 million in Q1 2026, $48.8 million in Q4 2025, and $503.9 million in Q3 2025.